• Noorfaiza A. Aziz Institute for Pathology, Laboratory and Forensic Medicine (I-PPerForM), Universiti Teknologi MARA, 47000 Sungai Buloh, Selangor, Malaysia
  • Gabriele Ruth Anisah Froemming Faculty of Medicine and Health Sciences, Universiti Malaysia Sarawak, 94300 Kota Samarahan, Sarawak, Malaysia
  • Siti Hamimah Sheikh Abdul Kadir Faculty of Medicine, Universiti Teknologi MARA, 47000 Sungai Buloh, Selangor, Malaysia
  • Mohammad Johari Ibahim Faculty of Medicine, Universiti Teknologi MARA, 47000 Sungai Buloh, Selangor, Malaysia




Telomerase activity, hTERT, Hsp90, p23, cisplatin, apigenin


Inhibition of telomerase activity has emerged as a promising strategy to combat cancer cells, especially ones with no specific molecular targets such as triple negative breast cancer (TNBC). Cisplatin, a chemotherapeutic drug, is causing DNA damage while apigenin, a plant-derived antioxidant, induces apoptosis in various cancer cell types. Little is known about their combined ability to inhibit telomerase activity in TNBC cells. In the current study, the effect of cisplatin in combination with apigenin was investigated with regards to telomerase activity and expression of the telomerase catalytic subunit hTERT as well as Heat Shock Protein 90 (Hsp90) and p23 in two types of TNBC (MDA-MB-231; HCC1806) and one non-tumorigenic (MCF10A) epithelial cell line. The results showed that the combined treatment of cisplatin and apigenin significantly down-regulated telomerase activity. The inhibition of telomerase activity was accompanied by a down-regulation of hTERT, Hsp90 and p23 at transcriptional and translational level in both TNBC cells, as compared to control cells. The results of the current study suggest that apigenin and cisplatin synergistically inhibit telomerase activity by downregulating the enzyme’s catalytic subunit. However, the exact roles of Hsp90 and p23 in the regulation of telomerase activity requires further investigation as they seem to be TNBC subtype-specific. 


Rakha, E. A., & Chan, S. 2011. Metastatic Triple-negative Breast Cancer. Clinical Oncology (Royal College of Radiologists (Great Britain)). 23(9): 587-600.

Anders, C. K., & Carey, L. a. 2009. Biology, Metastatic Patterns, and Treatment of Patients with Triple-negative Breast Cancer. Clinical Breast Cancer. 9 Suppl 2(June): S73-81.

Chen, C.-H., & Chen, R.-J. 2011. Prevalence of Telomerase Activity in Human Cancer. Journal of the Formosan Medical Association. 110(5): 275-89.

A. Carey, L., A. Hedican, C., S. Henderson, G., B. Umbricht, C., S. Dome, J., Varon, D., & Sukumar, S. 1998. Careful Histological Confirmation and Microdissection Reveal Telomerase Activity in Otherwise Telomerase-negative Breast Cancers. Clinical Cancer Research. 4(February): 435-440.

Ja, L., Cg, M., Tr, F., Hs, W., Je, L., Rubin, J., … Shay, J. W. 1996. Telomerase Activity in Human Breast Tumors. 88(2).

Shay, J. W., & Bacchetti, S. 1997. A Survey of Telomerase Activity in Human Cancer. European Journal of Cancer. 33(5): 787-91.

Shay, J. W., & Wright, W. E. 2010. Telomeres and Telomerase in Normal and Cancer Stem Cells. The Federation of European Biochemical Societies Letters. 584(17): 3819-25.

Mason, M., Schuller, A., & Skordalakes, E. 2011. Telomerase Structure Function. Current Opinion in Structural Biology. 21(1): 92-100.

Shammas, M. a, Koley, H., Batchu, R. B., Bertheau, R. C., Protopopov, A., Munshi, N. C., & Goyal, R. K. 2005. Telomerase Inhibition by siRNA Causes Senescence and Apoptosis in Barrett’s Adenocarcinoma Cells: Mechanism and Therapeutic Potential. Molecular Cancer. 4: 24.

Sekaran, V., Soares, J., & Jarstfer, M. B. 2014. Telomere Maintenance as a Target for Drug Discovery. Journal of Medicinal Chemistry. 57(3): 521-38.

Kang, S. H., Lee, H. J., Jeong, S. J., Kwon, H. Y., Kim, J. H., Yun, S. M., … Kim, S. H. 2009. Protective Effect of Bojungbangdocktang on Cisplatin-induced Cytotoxicity and Apoptosis in MCF-10A Breast Endothelial Cells. Environmental Toxicology and Pharmacology. 28(3): 430-438.

Keppler, B. R., Grady, A. T., & Jarstfer, M. B. 2006. The Biochemical Role of the Heat Shock Protein 90 Chaperone Complex in Establishing Human Telomerase Activity. The Journal of Biological Chemistry. 281(29): 19840-8.

Lee, J. H., & Chung, I. K. 2010. Curcumin Inhibits Nuclear Localization of Telomerase by Dissociating the Hsp90 co-chaperone p23 from hTERT. Cancer Letters. 290(1): 76-86.

Kim, R. H., Kim, R., Chen, W., Hu, S., Shin, K.-H., Park, N.-H., & Kang, M. K. 2008. Association of hsp90 to the hTERT promoter is Necessary for hTERT Expression in Human Oral Cancer Cells. Carcinogenesis. 29(12): 2425-31.

André, F., & Zielinski, C. C. 2012. Optimal strategies for the Treatment of Metastatic Triple-negative Breast Cancer with Currently Approved Agents. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 23 Suppl 6(Supplement 6): vi46–51.

Liu, M., Mo, Q.-G., Wei, C.-Y., Qin, Q.-H., Huang, Z., & He, J. 2013. Platinum-Based Chemotherapy In Triple-Negative Breast Cancer: A Meta-analysis. Oncology Letters. 5(3): 983-991.

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., … Garber, J. E. 2010. Efficacy of Neoadjuvant Cisplatin in Triple-negative Breast Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 28(7): 1145-53.

Singh, M., Chaudhry, P., Fabi, F., & Asselin, E. 2013. Cisplatin-induced caspase Activation Mediates PTEN Cleavage in Ovarian Cancer Cells: A Potential Mechanism of Chemoresistance. BioMed Central Cancer. 13: 233.

Dasari, S., & Bernard Tchounwou, P. 2014. Cisplatin in Cancer Therapy: Molecular Mechanisms of Action. European Journal of Pharmacology. 740: 364-378.

Brabec, V., & Kasparkova, J. 2005. Modifications of DNA by platinum Complexes. Relation to Resistance of Tumors to Platinum Antitumor Drugs. Drug resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 8(3): 131-46.

Cepeda, V., Fuertes, M. a, Castilla, J., Alonso, C., Quevedo, C., & Pérez, J. M. 2007. Biochemical Mechanisms of Cisplatin Cytotoxicity. Anti-cancer Agents in Medicinal Chemistry. 7(1): 3-18.

Bielawski, K., Czarnomysy, R., Muszyńska, A., Bielawska, A., & Popławska, B. 2013. Cytotoxicity and Induction of Apoptosis of Human Breast Cancer Cells by Novel Platinum(II) Complexes. Environmental Toxicology and Pharmacology. 35(2): 254-64.

Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. 2009. Natural Compounds for Cancer Treatment and Prevention. Pharmacological Research: The Official Journal of the Italian Pharmacological Society. 59(6): 365-78.

Demain, A. L., & Vaishnav, P. 2011. Natural Products for Cancer Chemotherapy. Microbial Biotechnology. 4(6): 687-699.

Gupta, S., Afaq, F., & Mukhtar, H. 2001. Selective Growth-inhibitory, Cell-cycle Deregulatory and Apoptotic Response of Apigenin in Normal Versus Human Prostate Carcinoma Cells. Biochemical and Biophysical Research Communications. 287(4): 914-20.

Atsuo, M. M., Asaki, N. S., Aga, K. S., & Aneko, T. K. 2005. Cytotoxicity of Flavonoids toward Cultured Normal Human Cells. Biological and Pharmaceutical Bulletin. 28(February): 253-259.

Choi, E. J., & Kim, G. 2009. Apigenin Induces Apoptosis through a Mitochondria/Caspase-Pathway in Human Breast Cancer MDA-MB-453 Cells. Journal of Clinical Biochemistry Nutrition. 44(3): 260-265.

Xu, Y., Xin, Y., Diao, Y., Lu, C., Fu, J., Luo, L., & Yin, Z. 2011. Synergistic effects of Apigenin and Paclitaxel on Apoptosis of Cancer Cells. PloS One. 6(12): e29169.

Zhu, Y., Mao, Y., Chen, H., Lin, Y., Hu, Z., Wu, J., … Xie, L. 2013. Apigenin Promotes Apoptosis, Inhibits Invasion and Induces Cell Cycle Arrest of T24 Human Bladder Cancer Cells. Cancer Cell International. 13(1): 54.

Al-Rashidi, R., Ibahim, M. J., Hasani, N. H., & Froemming, G. R. A. 2013. Tinospora Crispa is Ameliorating Cisplatin-Induced Cytotoxicity and Genotoxicity in Breast Epithelial Cells. Regenerative Research. 2(1): 31-40.

Ayasooriya, R. G. P. T., Kang, S.-H., Kang, C.-H., Choi, Y. H., Moon, D.-O., Hyun, J.-W., … Kim, G.-Y. 2012. Apigenin Decreases Cell Viability and Telomerase Activity in Human Leukemia Cell Lines. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association. 50(8): 2605-11.

Seo, H. S., Choi, H. S., Kim, S. R., Choi, Y. K., Woo, S. M., Shin, I., … Ko, S. K. 2012. Apigenin Induces Apoptosis Via Extrinsic Pathway, Inducing p53 and Inhibiting STAT3 and NF??B Signaling in HER2-overexpressing Breast Cancer Cells. Molecular and Cellular Biochemistry. 366(1-2), 319-334.

Choi, C. B., E. J., & Kim, G. 2009. Apigenin Induce Apoptosis through a Mitochondria / Caspase-Pathway in Human Breast Cancer MDA-MB-453 Cells. Journal of Clinical Biochemistry Nutrition. May: 260-265.

Zhang, T. ting, Yu, H. yang, Dong, G. lu, Cai, L., & Bai, Y. xian. 2013. Chamaejasmine Arrests Cell Cycle, Induces Apoptosis and Inhibits Nuclear NF-kB Translocation in the Human Breast Cancer Cell Line MDA-MB-231. Molecules, 18(1): 845-858.

Seo, H. S., Ju, J. H., Jang, K., & Shin, I. 2011. Induction of Apoptotic Cell Death by Phytoestrogens by Up-regulating the Levels of Phospho-p53 and p21 in Normal and Malignant Estrogen Receptor α-negative Breast Cells. Nutrition Research. 31(2): 139-146.

Chen, H., Li, Y., & Tollefsbol, T. O. 2009. Strategies Targeting Telomerase Inhibition. Molecular Biotechnology. 41(2): 194-199.

Dalle Carbonare, L., Valenti, M. T., Azzarello, G., Balducci, E., Crepaldi, G., Realdi, G., … Giannini, S. 2005. Bisphosphonates Decrease Telomerase Activity and hTERT Expression in MCF-7 Breast Cancer Cells. Molecular and Cellular Endocrinology. 240(1-2): 23-31.

Sun, P.-M., Wei, L.-H., Luo, M.-Y., Liu, G., Wang, J.-L., Mustea, A., … Sehouli, J. 2007. The Telomerase Activity And Expression of hTERT Gene Can Serve as Indicators in the Anti-cancer Treatment of Human Ovarian Cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 130(2): 249-57.

Lee, B. J., Lee, B. H., Wang, S. G., Lee, J. C., Roh, H. J., Goh, E. K., … Jun, E. S. 2007. Change of the Expression of Human Telomerase Reverse Transcriptase mRNA and Human Telomerase RNA After Cisplatin and 5-fluorouracil Exposure in Head and Neck Squamous Cell Carcinoma Cell Lines. Journal of Korean Medical Science. 22 Suppl(10): S73-S78.

Forsythe, H. L., Jarvis, J. L., Turner, J. W., Elmore, L. W., & Holt, S. E. 2001. Stable Association of hsp90 and p23, but Not hsp70, with Active Human Telomerase. The Journal of Biological Chemistry. 276(19): 15571-4.

Woo, S. H., An, S., Lee, H.-C., Jin, H.-O., Seo, S.-K., Yoo, D.-H., … Park, I.-C. 2009. A Truncated Form of p23 Down-regulates telomerase Activity via Disruption of Hsp90 Function. The Journal of Biological Chemistry. 284(45): 30871-80.

Zhao, M., Ma, J., Zhu, H.-Y., Zhang, X.-H., Du, Z.-Y., Xu, Y.-J., & Yu, X.-D. 2011. Apigenin Inhibits Proliferation and Induces Apoptosis in Human Multiple Myeloma Cells Through Targeting the Trinity of CK2, Cdc37 and Hsp90. Molecular Cancer. 10(1): 104.

Itoh, H., Ogura, M., Komatsuda, A., Wakui, H., Miura, A. B., & Tashima, Y. 1999. A novel Chaperone-activity-Reducing Mechanism of the 90-kDa Molecular Chaperone HSP90. Biochemical Journal. 344: 697-703.

Ishida R, Takaoka Y, Yamamoto S, Miyazaki T, Otaka M, Watanabe S, Komatsuda A, Wakui H, Sawada K, Kubota H, Itoh H. 2008. Cisplatin differently Affects Amino Terminal and Carboxyl Terminal Domains of HSP90. FEBS Lett. 582(28):3 879-83

Huang, P., Yang, J., & Song, Q. 2014. Atrazine Affects Phosphoprotein and Protein Expression in MCF-10A Human Breast Epithelial Cells. International Journal of Molecular Sciences. 15(10): 17806-26.

Shervington, a., Cruickshanks, N., Wright, H., Atkinson-Dell, R., Lea, R., Roberts, G., & Shervington, L. 2006. Glioma: What is the Role of c-Myc, hsp90 and Telomerase? Molecular and Cellular Biochemistry. 283(1-2): 1-9.

Holt, S. E., Aisner, D. L., Baur, J., Tesmer, V. M., Dy, M., Ouellette, M., … White, M. A. 1999. Functional Requirement of p23 and Hsp90 in Telomerase Complexes. Genes & Development. 13(7): 817-826.

Ruden, M., & Puri, N. 2013. Novel Anticancer Therapeutics Targeting Telomerase. Cancer Treatment Reviews. 39(5): 444-56.

Nakatani, Y., Hokonohara, Y., Kakuta, S., Sudo, K., Iwakura, Y., & Kudo, I. 2007. Knockout Mice Lacking cPGES/p23, a Constitutively Expressed PGE2 synthetic Enzyme, are Peri-Natally Lethal. Biochemical and Biophysical Research Communications. 362(2): 387-92.

Grad, I., McKee, T. a, Ludwig, S. M., Hoyle, G. W., Ruiz, P., Wurst, W., … Picard, D. 2006. The Hsp90 Cochaperone p23 is Essential for Perinatal Survival. Molecular and Cellular Biology. 26(23): 8976-83.

Simpson, N. E., Lambert, W. M., Watkins, R., Giashuddin, S., Huang, S. J., Oxelmark, E., … Garabedian, M. J. 2010. High Levels of Hsp90 Cochaperone p23 Promote Tumor Progression And Poor Prognosis In Breast Cancer By Increasing Lymph Node Metastases And Drug Resistance. Cancer Research. 70(21): 8446-56.




How to Cite

A. Aziz, N., Froemming, G. R. A., Sheikh Abdul Kadir, S. H., & Ibahim, M. J. (2017). APIGENIN INCREASES CISPLATIN INHIBITORY EFFECTS ON THE TELOMERASE ACTIVITY OF TRIPLE NEGATIVE BREAST CANCER CELLS. Jurnal Teknologi, 80(1). https://doi.org/10.11113/jt.v80.10378



Science and Engineering